Pharmacy World and Science

, Volume 26, Issue 3, pp 160–168 | Cite as

An economic evaluation of the costs and benefits of heparin rationalisation in a hospital pharmacy

  • Penny Reeves
  • Jonathan Cooke
  • Adam Lloyd
  • Adam Hutchings


Aim: To estimate the costs and benefits for a UK hospital pharmacy of stocking a single low molecular weight heparin (LMWH), enoxaparin, compared to stocking unfractionated heparin (UFH) and stocking both UFH and multiple different LMWHs.

Methods: A decision-tree model was developed which considered the use of heparins for five indications: prophylaxis against venous thromboembolism (VTE) in major orthopaedic surgery; VTE prophylaxis in major general surgery; VTE prophylaxis in acute medical inpatients; treatment of diagnosed VTE; and anticoagulation for patients with unstable angina and non-ST-elevation myocardial infarction (UA/NSTEMI). Previously published cost-effectiveness analyses for each indication were combined into a single model and updated to 2002 prices. The number of patients given heparin in each indication was estimated from the pharmacy records of a large UK teaching hospital. The model estimated the use of drugs, staff time, clinical events and resource use resulting from anti-coagulation. Costs were estimated from the perspective of the hospital and the UK National Health Service.

Results: Total annual cost was estimated to be £3.2 m (single LMWH), £4.4 m (UFH only) and £3.7 m (multiple heparins). The largest expected cost savings from using a single LMWH compared to UFH only resulted from reduced hospital stay for DVT treatment, reduced revascularisation in UA/NSTEMI and fewer VTE events in orthopaedic surgery. Expected cost savings from using a single LMWH compared to multiple heparins were more modest.

Conclusion: Sub-optimal choice of anticoagulants may result in substantial excess costs elsewhere in the hospital.

Economics Heparin Hospital pharmacy Pharmacy stock United Kingdom 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    British Medical Association. British National Formulary, 2002.Google Scholar
  2. 2.
    Electronic Medicines Compendium, 2002 ( Scholar
  3. 3.
    Department of Health. Building a safer NHS for patients: implementing an organisation with a memory. London, UK, 2001 ( Scholar
  4. 4.
    Child D, Cooke J, Moore P. Medication errors: outputs and actions from a web enabled hospital reporting system (HRS). Guild of Healthcare Pharmacists Annual National Conference, Manchester, UK, April 2002.Google Scholar
  5. 5.
    Bergqvist D, Lindgren B, Matzsch T. Comparison of the cost of preventing postoperative deep vein thrombosis with either unfractionated or low molecular weight heparin. Br J Surg 1996; 83: 1548–52.Google Scholar
  6. 6.
    Drummond M, Aristides M, Davies L, Forbes C. Economic evaluation of standard heparin and enoxaparin for prophylaxis against deep vein thrombosis in elective hip surgery. Br J Surg 1994; 81: 1742–6.Google Scholar
  7. 7.
    Lloyd AC, Anderson PM, Quinlan DJ, Bearne A. Economic evaluation of the use of enoxaparin for thromboprophylaxis in acutely ill medical patients. J Med Econom 2001; 4: 99–113.Google Scholar
  8. 8.
    Bosanquet N, Fox K. Longer term economic benefits reflect improved clinical outcomes with enoxaparin versus unfractionated heparin in acute coronary syndromes: one year data. Br J Cardiol 2001; 8: 36–7.Google Scholar
  9. 9.
    Hull RD, Pineo GF, Raskob GE. The economic impact of treating deep vein thrombosis with low-molecular-weight heparin: outcome of therapy and health economy aspects. Haemostasis 1998; 28(Suppl 3): 8–16.Google Scholar
  10. 10.
    Lloyd AC, Anderson PM, Quinlan DJ, Bearne A. Economic evaluation of the use of enoxaparin for thromboprophylaxis in acutely ill medical patients. J Med Econom 2001; 4: 99–113.Google Scholar
  11. 11.
    Valette F, Hoffmeyer U, Lloyd A. Economic evaluation of the use of tinzaparin in the treatment of deep vein thrombosis. Br J Med Econom 1995; 8: 111–23.Google Scholar
  12. 12.
    The Wessex Institute for Health Research and Development. Dalteparin and enoxaparin for unstable angina and non-Q-wave myocardial infarction: update. DEC Report 108. 2000.Google Scholar
  13. 13.
    Gozzard D, Lloyd A, Hutchinson J, Hutchings A. Economic evaluation of extended and conventional prophylaxis with enoxaparin against venous thromboembolism in patients undergoing surgery for abdominal cancer. Poster presentation at the International Congress on Thrombosis, Bologna, Italy, October, 2002.Google Scholar
  14. 14.
    Planes A, Vochelle N, Mazas F, Mansat C, Zucman J, Landais A et al. Prevention of postoperative venous thrombosis: a randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement. Thromb Haemost 1988; 60: 407–10.Google Scholar
  15. 15.
    Geerts WH, Heit JA, Clagett GP, Pineo GF, Colwell CW, Anderson Jr FA et al. Prevention of venous thromboembolism. Chest 2001; 119(Suppl 1): 132S-175S.Google Scholar
  16. 16.
    Palmer AJ, Schramm W, Kirchhof B, Bergemann R. Low molecular weight heparin and unfractionated heparin for prevention of thrombo-embolism in general surgery: a meta-analysis of randomised clinical trials. Haemostasis 1997; 27: 65–74.Google Scholar
  17. 17.
    Mismetti P, Laporte S, Darmon JY, Buchmuller A, Decousus H. Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery. Br J Surg 2001; 88: 913–30.Google Scholar
  18. 18.
    Samama MM, Cohen AT, Darmon JY, Desjardins L, Eldor A, Janbon C et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999; 341: 793–800.Google Scholar
  19. 19.
    Mismetti P, Laporte-Simitsidis S, Tardy B, Cucherat M, Buchmuller A, Juillard-Delsart D et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular-weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost 2000; 83: 14–9.Google Scholar
  20. 20.
    Dolovich LR, Ginsberg JS, Douketis JD, Holbrook AM, Cheah G. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med 2000; 160: 181–8.Google Scholar
  21. 21.
    Cohen M, Demers C, Gurfinkel EP, Turpie AG, Fromell GJ, Goodman S et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 1997; 337: 447–52.Google Scholar
  22. 22.
    Antman EM, Cohen M, Radley D, McCabe C, Rush J, Premmereur J et al. Assessment of the treatment effect of enoxaparin for unstable angina/non-Q-wave myocardial infarction. TIMI 11B-ESSENCE meta-analysis. Circulation 1999; 100: 1602–8.Google Scholar
  23. 23.
    Klein W, Buchwald A, Hillis S, Monrad S, Sanz G, Turpie AG. Comparison of low molecular weight heparin with unfractionated heparin acutely and with placebo for 6 weeks in the management of unstable coronary artery disease. Fragmin in unstable coronary artery disease study (FRIC). Circulation 1997; 96: 61–8.Google Scholar
  24. 24.
    Klein W, Buchwald A, Hillis S, Monrad S, Sanz G, Turpie AG. Fragmin in unstable angina pectoris or in non-Q-wave acute myocardial infarction (the FRIC study). Am J Cardiol 1997; 80: 30E-4E.Google Scholar
  25. 25.
    Finance Department, Wythenshawe Hospital. Average reference costs. Wythenshawe Hospital, Manchester, UK, 2002.Google Scholar
  26. 26.
    National Audit Commission. A Spoonful of Sugar: Medicines Management in NHS Hospitals. The Audit Commission, London, UK, 2001.Google Scholar
  27. 27.
    Davies L, Richardson GA. Economic evaluation of enoxaparin as post discharge prophylaxis against deep-vein thrombosis in elective hip surgery. Value Health 2000; 3(6): 397–406.Google Scholar
  28. 28.
    Netten A, Rees T, Harrison G. The Unit Costs of Health and Social Care. Canterbury, UK: Personal Social Services Research Unit (PSSRU), 2001.Google Scholar
  29. 29.
    Cohen A, Botteman M, Stephens J, Ewing M, Collier P, Pashos C et al. Cost effectiveness of two anticoagulants for the prophylaxis of DVT and subsequent long-term complications (PTS and recurrent VTE) in total hip replacement surgery in the United Kingdom. Poster presentation at the XVIIIth Congress of the International Society on Thrombosis and Haemostasis, Paris, France, July 2001.Google Scholar

Copyright information

© Kluwer Academic Publishers 2004

Authors and Affiliations

  • Penny Reeves
    • 1
  • Jonathan Cooke
    • 2
  • Adam Lloyd
    • 1
  • Adam Hutchings
    • 2
  1. 1.Fourth Hurdle Consulting LtdLondonUK
  2. 2.Wythenshawe HospitalManchesterUK

Personalised recommendations